Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis

Back

ESC Professional Premium Access

Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis

Session: Cardiac amyloidosis: how to stage and score

Topic: Infiltrative Myocardial Disease

Speaker: Doctor G. Sanna (Pavia, IT)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Giuseppe Damiano Sanna

Amyloidosis Research and Treatment Center, Pavia (Italy)

1 presentation

0 follower

7 more presentations in this session

Validation of two simple scores to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction

Speaker: Doctor M. Llevadot Sesmilo (Badalona, ES)

DPD quantification correlates with ECV and disease severity in patients with ATTR-CM

Speaker: Doctor R. Rettl (Vienna, AT)

Prognostic significance of right ventricular dysfunction in patients with TTR amyloidosis

Speaker: Doctor S. Istratoaie (Cluj Napoca, RO) Professor E. Donal (Rennes, FR)

Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms

Speaker: Doctor E. Oikonomou (New Haven, US)

Prognostic staging system correctly identifies high risk groups in cardiac transthyretin amyloidosis treated with tafamidis

Speaker: Mr M. Mueller (Berlin, DE)

Access the full session

Cardiac amyloidosis: how to stage and score

Speakers: Doctor G. Sanna, Doctor M. Llevadot Sesmilo, Doctor R. Rettl, Doctor S. Istratoaie, Professor E. Donal...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources